Reclusive trader scores 20 years of winning trades. Learn how.
He had 20 straight years of winning trades without a single losing year… He had 20 straight years of winning trades without a single losing year…

And now, he is coming forward to share a brand-new forecast.
Click here to watch the video now.
pixel
Robert A. Michael net worth and biography

Robert Michael Biography and Net Worth

Vice Chairman of AbbVie
Rob Michael is Vice Chairman, Finance and Commercial Operations and Chief Financial Officer, responsible for global commercial and financial operations of the company. He previously served as Executive Vice President, Chief Financial Officer.

Mr. Michael joined Abbott as a member of the Financial Development Program, and ultimately served as Division Controller, Nutrition Supply Chain and Division Controller, Abbott Molecular, among other roles.  After AbbVie’s separation from Abbott, Mr. Michael held a series of leadership roles of increasing responsibility including Vice President, Controller; Vice President, Treasurer; Vice President, Controller for Commercial Operations; and Vice President, AbbVie Financial Planning and Analysis.

He earned a bachelor’s degree in accounting from Indiana University Kelley School of Business and a master of business administration from University of California Los Angeles Anderson School of Management. He is also a Certified Public Accountant.

What is Robert A. Michael's net worth?

The estimated net worth of Robert A. Michael is at least $1.50 million as of February 28th, 2018. Mr. Michael owns 11,170 shares of AbbVie stock worth more than $1,499,126 as of September 30th. This net worth estimate does not reflect any other investments that Mr. Michael may own. Additionally, Mr. Michael receives a salary of $3,820,000.00 as Vice Chairman at AbbVie. Learn More about Robert A. Michael's net worth.

How old is Robert A. Michael?

Mr. Michael is currently 52 years old. There are 8 older executives and no younger executives at AbbVie. The oldest executive at AbbVie is Mr. Richard A. Gonzalez, Chairman & CEO, who is 68 years old. Learn More on Robert A. Michael's age.

What is Robert A. Michael's salary?

As the Vice Chairman of AbbVie Inc., Mr. Michael earned a total compensation package of $11,667,666.00 in 2021. Mr. Michael earned a salary of $1,129,881.00, stock awards of $4,258,823.00, options awards of $1,061,733.00, non-equity compensation of $2,630,000.00, and other compensation of $61,389.00.There are 2 executives that earn more than Mr. Michael. The highest earning executive at AbbVie is Mr. Richard A. Gonzalez, Chairman & CEO, who commands a salary of $7,420,000.00 per year. Learn More on Robert A. Michael's salary.

How do I contact Robert A. Michael?

The corporate mailing address for Mr. Michael and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Robert A. Michael's contact information.

Has Robert A. Michael been buying or selling shares of AbbVie?

Robert A. Michael has not been actively trading shares of AbbVie during the past quarter. Most recently, Robert A. Michael sold 43,105 shares of the business's stock in a transaction on Tuesday, March 1st. The shares were sold at an average price of $148.25, for a transaction totalling $6,390,316.25. Learn More on Robert A. Michael's trading history.

Who are AbbVie's active insiders?

AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.

Are insiders buying or selling shares of AbbVie?

During the last year, insiders at the sold shares 17 times. They sold a total of 1,048,944 shares worth more than $146,558,841.47. The most recent insider tranaction occured on May, 23rd when Vice Chairman Michael Severino sold 79,801 shares worth more than $12,041,970.90. Insiders at AbbVie own 0.1 % of the company. Learn More about insider trades at AbbVie.

Information on this page was last updated on 5/23/2022.

Robert A. Michael Insider Trading History at AbbVie

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/1/2022Sell43,105$148.25$6,390,316.25View SEC Filing Icon  
2/28/2018Sell4,294$119.43$512,832.4211,170View SEC Filing Icon  
2/20/2018Sell992$120.31$119,347.52View SEC Filing Icon  
9/28/2017Sell6,699$88.00$589,512.0010,007View SEC Filing Icon  
3/10/2017Sell5,132$65.29$335,068.2816,706View SEC Filing Icon  
See Full Table

Robert A. Michael Buying and Selling Activity at AbbVie

This chart shows Robert A Michael's buying and selling at AbbVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AbbVie Company Overview

AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $134.21
Low: $134.09
High: $142.33

50 Day Range

MA: $141.00
Low: $134.21
High: $151.15

2 Week Range

Now: $134.21
Low: $106.86
High: $175.91

Volume

15,336,473 shs

Average Volume

6,873,221 shs

Market Capitalization

$237.30 billion

P/E Ratio

19.01

Dividend Yield

3.95%

Beta

0.72